Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities

NCT04525300 on ClinicalTrials.gov · last registry update 2020-08-25

300 participants. Its estimated completion date, June 2022, has passed with no update to the record. Primary outcome, as filed: The composition of the gut microbiota from baseline to end of treatment. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Xiangya Hospital of Central South University
Sponsor type: Other
Enrollment: 300
Started: 2020-05-24
Primary completion: 2022-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The composition of the gut microbiota from baseline to end of treatment.

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.